Why Early Treatment Is Critical

Without timely and effective care for osteonecrosis of the femoral head (ONFH), up to 80% of patients develop femoral head collapse and end‑stage degenerative joint disease within 20 years, often requiring total hip arthroplasty (THA). While THA relieves pain and improves mobility, it is limited in younger patients-implants are not lifelong, and many will face revision surgery. For younger adults with ONFH, early joint‑preserving (head‑preserving) treatment is essential. Modern joint‑sparing procedures have shown promising clinical results.

 

Who Is Affected & Key Causes

ONFH most often affects people aged 20–40, with a global prevalence exceeding 20 million; incidence is higher in Asia than in Europe and North America.

Causes fall into two categories:

Direct risk factors: hip fracture, dislocation, sickle cell disease, radiation therapy

Indirect risk factors: corticosteroid use, excessive alcohol, certain metabolic syndromes, smoking

The top three modifiable risks are corticosteroids, alcohol, and trauma. Many cases have no clear identifiable cause.

 

Staging Systems (Clinically Used Worldwide)

2019 ARCO Staging

Stage 1: Normal X‑ray; positive MRI or bone scan

Stage 2: Abnormal X‑ray (sclerosis, focal osteopenia, cystic changes); no subchondral or necrotic fracture, no flattening

Stage 3: Subchondral or necrotic fracture visible on X‑ray/CT

3A: collapse ≤2 mm

3B: collapse >2 mm

Stage 4: Secondary osteoarthritis, joint space narrowing, acetabular changes, with or without joint destruction

Ficat‑Arlet Classification

Stage 0: Asymptomatic; normal imaging

Stage I: Mild symptoms; normal X‑ray

Stage IIa: Mild symptoms; normal contour, sclerosis, cysts

Stage IIb: Moderate symptoms; flattening of the femoral head

Stage III: Moderate–severe symptoms; collapse, loss of sphericity

Stage IV: Severe symptoms; acetabular damage alongside femoral head changes

 

Signs & Symptoms

Pain in the groin, gluteal area, and/or knee

Worse pain with hip internal rotation

Markedly reduced hip range of motion (may indicate advanced collapse)

Diagnosis: MRI is highly sensitive (93%) and specific (91%) for early ONFH. Used with X‑ray and CT to rule out impingement, tendinitis, or osteoarthritis.

Joint‑Preserving Treatments for ONFH

Without intervention, 67% of asymptomatic and 85% of symptomatic ONFH lesions progress to collapse.

Non‑Surgical Options

Bisphosphonates, statins, prostaglandins, hyperbaric oxygen, extracorporeal shockwave therapy

Surgical Joint‑Preserving Procedures

Core decompression (CD)

Multiple drilling

Femoral rotational osteotomy

Non‑vascularized bone graft

Vascularized bone graft

Porous tantalum rod implantation

Core decompression is the first‑line surgical option for pre‑collapse ONFH:

Reduces intraosseous pressure and relieves bone marrow edema

Breaks sclerotic bone to improve blood flow and neovascularization

To lower collapse risk, CD is often combined with bone grafting for structural support. Recent research shows added benefits with platelet‑rich plasma (PRP) or mesenchymal stem cells to boost osteogenesis, chondrogenesis, and angiogenesis.

 

---

Cistanche Tubulosa: Natural Support for Men's Bone Health

Why Cistanche Tubulosa Benefits Bone Health

Echinacoside and acteoside - key active compounds in Cistanche Tubulosa - help maintain bone health through multiple pathways:

Promote osteoblast proliferation and differentiation

Accelerate bone matrix synthesis and mineralization

Increase bone mineral density and strength

Improve microcirculation

Strongly inhibit osteoclast activity

Reduce oxidative stress–induced bone cell apoptosis

Correct the imbalance between bone resorption and formation

Support bone marrow hematopoiesis and nutrient supply

Alleviate fatty degeneration of bone marrow

Relieve inflammatory responses

This makes Cistanche Tubulosa valuable for:

Supporting bone metabolism

Helping protect against femoral head necrosis, bone atrophy, osteoporosis

Relieving lumbar and knee discomfort

Our Strength: High‑Potency Cistanche Tubulosa Extract

We are Chengdu Wecistanche Bio‑Tech Co., Ltd., the world's largest vertically integrated manufacturer of Cistanche Tubulosa extract with full industrial chain control:

200,000‑mu dedicated Cistanche Tubulosa plantation

20,000‑mu seed breeding base

GMP‑certified production with 100,000‑class cleanroom

Advanced ultrafiltration / nanofiltration purification

14 invention patents including membrane separation technology

Certifications: SC, HACCP, ISO, NOP, Organic, Halal, Kosher

We specialize in Cistanche Tubulosa (not common desert Cistanche), which delivers higher echinacoside and acteoside content - ideal for consistent, research‑aligned bone and men's health support.

About Us

Supportive Service Of Wecistanche-For more details about cooperation

Email:Lijianlin@wecistanche.com

 

---

 

This article is for educational and informational purposes only. It is not intended to be medical advice, diagnosis, or treatment. Osteonecrosis of the femoral head is a serious orthopedic condition that requires evaluation and management by a qualified medical professional. Always consult a licensed physician before starting any supplement, herbal product, or new health regimen. Do not disregard professional medical advice or delay seeking care because of information you have read here. Supplements are not intended to replace standard medical treatments.